President & CEO
President & CEO
Debra Miller co-founded CureDuchenne in 2003 with her husband, Paul, after their only son was diagnosed with Duchenne. Miller relies on her extensive background in sales and marketing to lead CureDuchenne.
Her role includes overseeing all operations, research and financial resources as well as serving as the primary liaison to the Board of Directors. She is the decision maker, leader and manager in carrying out the mission of the organization. She also works closely with the Scientific Board of Advisors in designing and implementing the medical research strategic plan.
Miller earned a Bachelor of Arts in Communication Studies from the University of California Los Angeles. Prior to CureDuchenne, she had a career in publishing with positions in advertising sales and was an independent stock trader.
Chief Scientific Advisor
Dr. Michael Kelly joined CureDuchenne in December 2011 as chief scientific officer. Kelly, a senior pharmaceutical executive, brings more than 25 years experience in drug discovery and development to the organization. He is responsible for advancing drug development programs and identifying new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.
Before joining CureDuchenne, Kelly served as president and U.S. site head of Renovis, Inc. and has held senior positions at Amgen, Inc., Wyeth (Pfizer) and Wellcome (GlaxoSmithKline).
Kelly holds a Ph.D. from the University of Southampton (U.K.), held research positions at the University of Michigan and University of Nottingham, is an inventor on more than 100 patents and is widely published in peer reviewed journals.
Eastern Director of Development
Meg Wood joined the CureDuchenne team in 2016 as the Eastern Director of Development. She is a ten year veteran of Boston’s healthcare & biotechnology industry, most recently coming from MPM Capital – an early stage venture group. At MPM Capital, Meghan was marketing lead for several investment funds including the Oncology Impact Fund ($450M) for early stage oncology science.
Before MPM Capital, Meg was a public health manager at Tufts Medical Center and Boston Medical Center. She was responsible for hospital population management, ambulatory patient experience, and patient cost saving initiatives. Meg has both a Master of Public Health and Master of Social Work degree from Boston University.
Jen Maduko joined CureDuchenne in June 2017 as the Development Manager. Her role at the organization is to support the Senior Development Director in the successful planning and execution of Newport in Napa and the Getzlaf Golf Shootout.
Jen has 5 years of development experience that encompasses donor engagement, event planning, proposal management, and relationship building. Prior to joining CureDuchenne, Jen worked for the organization CoachArt as the Development Manager for Los Angeles focusing on securing sponsorships for the annual CoachArt Gala of Champions and managing a $1.28M fundraising goal. She also had success securing $300M in proposal wins for the engineering consulting firm Tetra Tech. Jen has a Master’s in Public Policy from Pepperdine, a Bachelor’s in English from the University of California, Riverside, and is a member of the professional organization AFP.
Family Resource Manager
Tiffany Cook joined the team in June 2017 as Family Resource Manager of CureDuchenne. Her role is to create and present family education materials and investigate new ways to help families work with schools, insurance companies, clinicians, and other means of improving the lives of those families living with Duchenne. Tiffany will also be developing and leading fundraising efforts in the southern region of the United States.
Tiffany is a New Orleans native and graduate of the Academy of the Sacred Heart (’90). She earned her BA in Communicative Disorders from The University of Alabama (’94) and MS in Speech Language Pathology from Nova Southeastern University (’97). She began her career in South Florida with continuation in Southern California and North Texas.
When families are told that their child has Duchenne, the world stops. Tiffany’s son, Wil, was diagnosed with Duchenne in 2007. She was confirmed as a Carrier for Duchenne in 2008. From Duchenne, she has learned to live – to live in and for the moment every single day. Duchenne challenges us to think and do things differently. Her twenty plus year career as a school based Speech-Language Pathologist has inspired her to cultivate communicative environments that foster the social and emotional well-being of people. Tiffany resides in Dallas with her husband, son, and daughter.
Community Engagement Manager
Kylee Groon joined CureDuchenne in January 2017 as Community Engagement Manager. Her role at the organization is to work with Duchenne families near and far to build supportive relationships between them and the organization. She is responsible for engaging Duchenne families, further connecting them to their communities. With the support of Duchenne families all over the nation, CureDuchenne continues to assist in finding a treatment for all boys living with Duchenne muscular dystrophy.
Kylee comes from a background of strategic communication having a Bachelor of Journalism from University of Missouri. She set her primary educational focus on developing campaigns for non profit organizations while also devoting time to serve both her campus and community. During her college career she completed internships at Make-A-Wish® Orange County and the Inland Empire and Children’s Miracle Network- Columbia. In both roles she gained knowledge of how to work alongside children and families as well as skills in marketing, communications, social media, fundraising and development.